The COVID-19 Vaccines: Recent Development, Challenges and Prospects
The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed dru...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
Multidisciplinary Digital Publishing Institute
2021
|
| Online Access: | https://hdl.handle.net/1721.1/130431 |
| _version_ | 1811095408566337536 |
|---|---|
| author | Yan, Yuxin Pang, Yoongxin Lyu, Zhuoyi Wang, Ruiqi Wu, Xinyun You, Chong Zhao, Haitao Manickam, Sivakumar Lester, Edward Wu, Tao Pang, Cheng Heng |
| author2 | Massachusetts Institute of Technology. Department of Mechanical Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Mechanical Engineering Yan, Yuxin Pang, Yoongxin Lyu, Zhuoyi Wang, Ruiqi Wu, Xinyun You, Chong Zhao, Haitao Manickam, Sivakumar Lester, Edward Wu, Tao Pang, Cheng Heng |
| author_sort | Yan, Yuxin |
| collection | MIT |
| description | The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed drugs to control the outbreak. The development of COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy, and a collective global effort has been invested into protection against SARS-CoV-2. As of March 2021, thirteen vaccines have been approved for application whilst over 90 vaccine candidates are under clinical trials. This review focuses on the development of COVID-19 vaccines and highlights the efficacy and vaccination reactions of the authorised vaccines. The mechanisms, storage, and dosage specification of vaccine candidates at the advanced stage of development are also critically reviewed together with considerations for potential challenges. Whilst the development of a vaccine is, in general, in its infancy, current progress is promising. However, the world population will have to continue to adapt to the “new normal” and practice social distancing and hygienic measures, at least until effective vaccines are available to the general public. |
| first_indexed | 2024-09-23T16:16:17Z |
| format | Article |
| id | mit-1721.1/130431 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2024-09-23T16:16:17Z |
| publishDate | 2021 |
| publisher | Multidisciplinary Digital Publishing Institute |
| record_format | dspace |
| spelling | mit-1721.1/1304312022-10-02T07:25:52Z The COVID-19 Vaccines: Recent Development, Challenges and Prospects Yan, Yuxin Pang, Yoongxin Lyu, Zhuoyi Wang, Ruiqi Wu, Xinyun You, Chong Zhao, Haitao Manickam, Sivakumar Lester, Edward Wu, Tao Pang, Cheng Heng Massachusetts Institute of Technology. Department of Mechanical Engineering The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed drugs to control the outbreak. The development of COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy, and a collective global effort has been invested into protection against SARS-CoV-2. As of March 2021, thirteen vaccines have been approved for application whilst over 90 vaccine candidates are under clinical trials. This review focuses on the development of COVID-19 vaccines and highlights the efficacy and vaccination reactions of the authorised vaccines. The mechanisms, storage, and dosage specification of vaccine candidates at the advanced stage of development are also critically reviewed together with considerations for potential challenges. Whilst the development of a vaccine is, in general, in its infancy, current progress is promising. However, the world population will have to continue to adapt to the “new normal” and practice social distancing and hygienic measures, at least until effective vaccines are available to the general public. 2021-04-09T19:28:02Z 2021-04-09T19:28:02Z 2021-04 2021-03 2021-04-09T13:47:54Z Article http://purl.org/eprint/type/JournalArticle 2076-393X https://hdl.handle.net/1721.1/130431 Yan, Yuxin et al. "The COVID-19 Vaccines: Recent Development, Challenges and Prospects." Vaccines 9, 4 (April 2021): 349 © 2021 The Authors http://dx.doi.org/10.3390/vaccines9040349 Vaccines Creative Commons Attribution https://creativecommons.org/licenses/by/4.0/ application/pdf Multidisciplinary Digital Publishing Institute Multidisciplinary Digital Publishing Institute |
| spellingShingle | Yan, Yuxin Pang, Yoongxin Lyu, Zhuoyi Wang, Ruiqi Wu, Xinyun You, Chong Zhao, Haitao Manickam, Sivakumar Lester, Edward Wu, Tao Pang, Cheng Heng The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
| title | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
| title_full | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
| title_fullStr | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
| title_full_unstemmed | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
| title_short | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
| title_sort | covid 19 vaccines recent development challenges and prospects |
| url | https://hdl.handle.net/1721.1/130431 |
| work_keys_str_mv | AT yanyuxin thecovid19vaccinesrecentdevelopmentchallengesandprospects AT pangyoongxin thecovid19vaccinesrecentdevelopmentchallengesandprospects AT lyuzhuoyi thecovid19vaccinesrecentdevelopmentchallengesandprospects AT wangruiqi thecovid19vaccinesrecentdevelopmentchallengesandprospects AT wuxinyun thecovid19vaccinesrecentdevelopmentchallengesandprospects AT youchong thecovid19vaccinesrecentdevelopmentchallengesandprospects AT zhaohaitao thecovid19vaccinesrecentdevelopmentchallengesandprospects AT manickamsivakumar thecovid19vaccinesrecentdevelopmentchallengesandprospects AT lesteredward thecovid19vaccinesrecentdevelopmentchallengesandprospects AT wutao thecovid19vaccinesrecentdevelopmentchallengesandprospects AT pangchengheng thecovid19vaccinesrecentdevelopmentchallengesandprospects AT yanyuxin covid19vaccinesrecentdevelopmentchallengesandprospects AT pangyoongxin covid19vaccinesrecentdevelopmentchallengesandprospects AT lyuzhuoyi covid19vaccinesrecentdevelopmentchallengesandprospects AT wangruiqi covid19vaccinesrecentdevelopmentchallengesandprospects AT wuxinyun covid19vaccinesrecentdevelopmentchallengesandprospects AT youchong covid19vaccinesrecentdevelopmentchallengesandprospects AT zhaohaitao covid19vaccinesrecentdevelopmentchallengesandprospects AT manickamsivakumar covid19vaccinesrecentdevelopmentchallengesandprospects AT lesteredward covid19vaccinesrecentdevelopmentchallengesandprospects AT wutao covid19vaccinesrecentdevelopmentchallengesandprospects AT pangchengheng covid19vaccinesrecentdevelopmentchallengesandprospects |